Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 115 peer-reviewed journal articles Updated
Oncology

Navigating Your New Reality: Understanding CML

At a Glance

Chronic Myeloid Leukemia (CML) is a highly manageable blood cancer caused by a genetic mutation called the Philadelphia chromosome. Today, it is typically treated with daily targeted oral medications called TKIs, allowing most patients to experience a near-normal life expectancy.

Hearing the word “leukemia” is life-altering, and it is natural to feel a sense of panic. However, it is important to know that Chronic Myeloid Leukemia (CML) is a unique success story in modern medicine. While it is a rare cancer—affecting roughly 1 to 2 people out of every 100,000—the way it is treated has undergone a complete revolution [1][2]. For most people diagnosed today, CML is no longer a life-threatening emergency, but a manageable chronic condition, much like high blood pressure or diabetes [3][4].

Stabilizing Facts

When you are first diagnosed, the volume of information can feel overwhelming. These three facts provide a foundation for understanding your new reality:

  1. Near-Normal Life Expectancy: With current treatments, many people with CML have a life expectancy that is nearly identical to someone who does not have the disease [2][5].
  2. A Pill, Not a Hospital Stay: The standard treatment for CML is not traditional intravenous chemotherapy. Instead, most patients take a daily oral medication called a Tyrosine Kinase Inhibitor (TKI) that they can take at home [6][7].
  3. Remission Without Medication: For many patients who respond exceptionally well to treatment over several years, it may eventually be possible to stop taking the medication entirely under close medical supervision—a goal known as Treatment-Free Remission [8][9].

Understanding the Philadelphia Chromosome

CML is caused by a very specific genetic “glitch” that happens in your bone marrow cells. This glitch is called the Philadelphia Chromosome (or t(9;22)).

Think of your DNA as a library of instruction manuals (chromosomes). In CML, a piece of “manual” number 9 and a piece of “manual” number 22 break off and swap places [10][11]. This swap creates a brand-new, abnormal gene called BCR-ABL1 [10]. This new gene acts like a “stuck” power switch, sending a constant signal to your body to produce too many white blood cells [7]. Detecting this chromosome is how doctors confirm you have CML [12]. To read more about the biology of this disease, see The Biology of CML.

The Role of TKIs

Modern treatments, called Tyrosine Kinase Inhibitors (TKIs), were designed specifically to target the protein made by the BCR-ABL1 gene. You can think of the TKI as a customized key that fits into that “stuck” power switch and turns it off [7][13]. By blocking this signal, the TKI stops the overproduction of leukemia cells, allowing your healthy blood cells to return to normal levels [14][15]. See Targeted Therapy: Navigating Your Treatment Options.

The Chronic Phase

The vast majority of patients (about 90-95%) are diagnosed in the Chronic Phase. This means the disease is stable, moving slowly, and usually causes few or mild symptoms, such as fatigue or a feeling of fullness in the abdomen [6]. While CML can progress to more aggressive stages if left untreated, the goal of modern TKI therapy is to keep the disease in this manageable chronic state indefinitely or drive it into a Deep Molecular Response (DMR), where the leukemia is barely detectable even with highly sensitive tests [16][17]. For more on this, see The Phases of CML.

A New Standard of Care

Current clinical guidelines from leading organizations like the NCCN (National Comprehensive Cancer Network) emphasize that treatment should be personalized [15]. Your doctor will choose a TKI based on your specific health history and lifestyle, with the goal of not just “treating” the cancer, but ensuring you can live a full, active life [18][19]. Long-term monitoring through regular blood tests is the “new normal” for CML patients, ensuring the medication continues to work effectively [20][21]. Learn how to build your medical team in Building Your Care Team.

In this guide

7 chapters

01

The Biology of CML: Why Your Cells Grow Out of Control

Understand the biology of Chronic Myeloid Leukemia (CML). Learn about the Philadelphia chromosome, the BCR-ABL1 gene, and the tests used for diagnosis.

02

The Phases of CML: Understanding Disease Progression

Understand the phases of Chronic Myeloid Leukemia (CML). Learn how doctors classify Chronic, Accelerated, and Blast phases and monitor your disease progression.

03

Predicting Your Progress: Understanding CML Risk Scores

Learn how CML risk scores like ELTS and Sokal are calculated using age, spleen size, and blood counts, and how they help choose the best TKI treatment.

04

Reading Your "Scorecard": Decoding CML Lab Reports

Learn how to read your CML lab reports and understand BCR-ABL1 PCR test results. Discover what the International Scale, log reductions, and MMR mean for you.

05

Targeted Therapy: Navigating Your Treatment Options

Learn about Chronic Myeloid Leukemia (CML) targeted therapies. Understand TKI options, asciminib, adherence, side effects, and managing drug resistance.

06

Building Your Care Team: Preparing for the First Visit

Learn how to build an expert care team for Chronic Myeloid Leukemia (CML). Discover what to bring to your first visit, questions to ask, and care guidelines.

07

The Long Game: Monitoring, Side Effects, and Remission

Learn about long-term Chronic Myeloid Leukemia (CML) care. Understand BCR-ABL1 molecular milestones, managing TKI side effects, and Treatment-Free Remission.

Common questions in this guide

Is a Chronic Myeloid Leukemia diagnosis a life-threatening emergency?
For most people diagnosed today, CML is no longer a life-threatening emergency. It is generally managed as a chronic condition with daily targeted medication, and many patients have a near-normal life expectancy.
What is the Philadelphia chromosome in CML?
The Philadelphia chromosome is a genetic change in the bone marrow cells where pieces of chromosomes 9 and 22 swap places. This swap creates an abnormal gene called BCR-ABL1, which signals the body to overproduce white blood cells.
How is CML usually treated?
The standard treatment for CML is a daily oral pill called a Tyrosine Kinase Inhibitor (TKI), rather than traditional intravenous chemotherapy. These pills specifically target and turn off the abnormal signals causing leukemia cells to multiply.
What does it mean to be in the chronic phase of CML?
Being in the chronic phase means the disease is stable and moving slowly, often causing few or only mild symptoms like fatigue. The vast majority of patients are diagnosed in this early, manageable phase.
Will I have to take CML medication for the rest of my life?
While many patients take medication indefinitely, some who respond exceptionally well over several years may achieve Treatment-Free Remission. This means they can safely stop taking the medication while being closely monitored by their doctor.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What was my BCR-ABL1 level at diagnosis, and what are our specific targets for the next three, six, and twelve months?
  2. 2.Given my other health history, which Tyrosine Kinase Inhibitor (TKI) do you recommend as my first-line treatment and why?
  3. 3.Is my CML currently in the 'chronic phase,' and what does that mean for my day-to-day life and long-term outlook?
  4. 4.What symptoms or side effects should I report to you immediately, and how will we manage the more common ones like fatigue or nausea?
  5. 5.If I respond well to treatment over several years, is 'Treatment-Free Remission' a potential goal for me in the future?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Innovation in hematology. Perspectives: CML 2016.

    Hehlmann R

    Haematologica 2016; (101(6)):657-9 doi:10.3324/haematol.2016.142877.

    PMID: 27252510
  2. 2

    The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission.

    Andrews C, Lipton J

    Leukemia & lymphoma 2019; (60(13)):3099-3101 doi:10.1080/10428194.2019.1665667.

    PMID: 31556337
  3. 3

    Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors.

    Sasaki K, Kantarjian HM, Jain P, et al.

    Cancer 2016; (122(2)):238-48 doi:10.1002/cncr.29745.

    PMID: 26479889
  4. 4

    Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.

    Rabian F, Lengline E, Rea D

    Current hematologic malignancy reports 2019; (14(6)):492-500 doi:10.1007/s11899-019-00546-4.

    PMID: 31760572
  5. 5

    Further augmentation of molecular responses with dasatinib therapy in chronic myeloid leukemia patients who gained major molecular response under imatinib.

    Eskazan AE

    International journal of clinical oncology 2018; (23(2)):400-401 doi:10.1007/s10147-017-1214-y.

    PMID: 29134363
  6. 6

    Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology.

    Radich JP, Deininger M, Abboud CN, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2018; (16(9)):1108-1135 doi:10.6004/jnccn.2018.0071.

    PMID: 30181422
  7. 7

    Harmonizing the craft of crafting clinically endorsed small-molecule BCR-ABL tyrosine kinase inhibitors for the treatment of hematological malignancies.

    Sun L, Yang PC, Luan L, et al.

    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2024; (193()):106678 doi:10.1016/j.ejps.2023.106678.

    PMID: 38114052
  8. 8

    Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.

    Legros L, Nicolini FE, Etienne G, et al.

    Cancer 2017; (123(22)):4403-4410 doi:10.1002/cncr.30885.

    PMID: 28743166
  9. 9

    Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

    Rea D, Ame S, Berger M, et al.

    Cancer 2018; (124(14)):2956-2963 doi:10.1002/cncr.31411.

    PMID: 29723417
  10. 10

    A double Philadelphia chromosome-positive chronic myeloid leukemia patient, co-expressing P210BCR-ABL1 and P195BCR-ABL1 isoforms.

    Vinhas R, Lourenço A, Santos S, et al.

    Haematologica 2018; (103(11)):e549-e552 doi:10.3324/haematol.2018.192534.

    PMID: 30093395
  11. 11

    Development, Function, and Clinical Significance of Plasmacytoid Dendritic Cells in Chronic Myeloid Leukemia.

    Inselmann S, Wang Y, Saussele S, et al.

    Cancer research 2018; (78(21)):6223-6234 doi:10.1158/0008-5472.CAN-18-1477.

    PMID: 30166420
  12. 12

    Determination of cDNA encoding BCR/ABL fusion gene in patients with chronic myelogenous leukemia using a novel FRET-based quantum dots-DNA nanosensor.

    Shamsipur M, Nasirian V, Barati A, et al.

    Analytica chimica acta 2017; (966()):62-70 doi:10.1016/j.aca.2017.02.015.

    PMID: 28372728
  13. 13

    Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy.

    Rossari F, Minutolo F, Orciuolo E

    Journal of hematology & oncology 2018; (11(1)):84 doi:10.1186/s13045-018-0624-2.

    PMID: 29925402
  14. 14

    New Methodologies in the Molecular Monitoring of CML.

    Yeung CC, Egan D, Radich J

    Current hematologic malignancy reports 2016; (11(2)):94-101 doi:10.1007/s11899-016-0303-8.

    PMID: 26946301
  15. 15

    Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.

    Deininger MW, Shah NP, Altman JK, et al.

    Journal of the National Comprehensive Cancer Network : JNCCN 2020; (18(10)):1385-1415.

    PMID: 33022644
  16. 16

    Beyond the comfort zone of deep molecular response: discontinuation in major molecular response chronic myeloid leukemia.

    Dragani M, Rege-Cambrin G, Ferrero D, et al.

    Leukemia & lymphoma 2019; (60(13)):3330-3332 doi:10.1080/10428194.2019.1622103.

    PMID: 31161827
  17. 17

    Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.

    Saussele S, Richter J, Guilhot J, et al.

    The Lancet. Oncology 2018; (19(6)):747-757 doi:10.1016/S1470-2045(18)30192-X.

    PMID: 29735299
  18. 18

    Moving on from 2013 to 2020 European LeukemiaNet recommendations for treating chronic myeloid leukemia: what has changed over the 7 years?

    Yilmaz U, Eskazan AE

    Expert review of hematology 2020; (13(10)):1035-1038 doi:10.1080/17474086.2020.1813564.

    PMID: 32814447
  19. 19

    Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia.

    Gustafson D, Fish JE, Lipton JH, Aghel N

    Current hematologic malignancy reports 2020; (15(1)):20-30 doi:10.1007/s11899-020-00560-x.

    PMID: 32078113
  20. 20

    Revisiting Treatment-free Remission: A Case of Late Molecular Recurrence in Chronic Myeloid Leukemia.

    Sharma V, Digwal A, Bagrodia V, Sharma M

    The Journal of the Association of Physicians of India 2025; (73(9S)):21-22 doi:10.59556/japi.73.1123.

    PMID: 40955978
  21. 21

    Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission.

    Lu L, Kok CH, Dang P, et al.

    British journal of haematology 2022; (198(3)):600-603 doi:10.1111/bjh.18277.

    PMID: 35620965

This page provides a general overview of Chronic Myeloid Leukemia (CML) for educational purposes only. It does not replace professional medical advice from your oncologist or hematologist regarding your specific diagnosis and treatment plan.

Get notified when new evidence is published on Chronic myeloid leukemia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.